Sneha Mehrotra, President of KCL Oncology Society, shared a post on LinkedIn:
“I am grateful to have had the incredible opportunity to present two posters at this year’s International Urology Cancer Summit (IUCS), and thrilled that both our abstracts were published in The Oncologist (Oxford University Press):
One of our abstracts was shortlisted as a finalist, and I was honoured to deliver a further mini-oral presentation on our research into biomarkers for detecting minimal residual disease (MRD) in operable urothelial cancer.
It was a wonderful experience working alongside Ankita Redla and having invaluable mentorship and support from Aruni Ghose.
As we write up our full manuscripts, I am excited to continue exploring how biomarkers such as circulating tumour DNA (ctDNA) can transform cancer detection, risk stratification, and treatment in the years ahead.”
Title: IUC24417-83 Correlation of circulating tumor DNA with oncological endpoints in metastatic urothelial cancer: a systematic review and meta-analysis of phase II/III clinical trials
Authors: S Mehrotra, A C Redla, J K Tan, A Ghose, A Maniam, S Boussios, G L Banna, P Das, S Adeleke, A Sharma
Title: IUC24418-84 Biomarkers detecting minimal residual disease for predicting risk of relapse in operable urothelial cancer: a systematic review and meta-analysis of phase II/III clinical trials
Authors: A C Redla, S Mehrotra, J K Tan, A Ghose, A Shah, P Kotecha, A Sharma, P Das, J Teoh, N Vasdev
Read Further: Highlights from IUCS 2025.
